Results 71 to 80 of about 2,377 (150)

Personalized Treatment of Patients With Multiple Sclerosis: A Case Report and Literature Review

Medicine Bulletin, Volume 2, Issue 3, Page 312-318, June 2026.
ABSTRACT Managing multiple sclerosis (MS) with a highly active disease course presents significant challenges, particularly regarding the timing of therapeutic escalation and the preservation of brain volume. We present a personalized management strategy for a 36‐year‐old male with relapsing‐remitting MS (RRMS) who experienced initial misdiagnosis ...
Fengjun Wang, Han Wang, Yu Zhang, Guoxun Zhang   +3 more
wiley   +1 more source

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models

, 2022
International audienceBackground and Objectives Siponimod is an oral, selective sphingosine-1-phosphate receptor-1/5 modulator approved for treatment of multiple sclerosis.Methods Mouse MRI was used to investigate remyelination in the cuprizone model. We
Bigaud, Marc, Levkau, Bodo, Lubetzki, Catherine, Tisserand, Sarah, Gruchot, Joel, Stankoff, Bruno, Köhrer, Karl, Meuth, Sven Günther, Petzsch, Patrick, Beerli, Christian, Issberner, Andrea, Shimshek, Derya, Dietrich, Michael, Hartung, Hans-Peter, Langui, Dominique, Göttle, Peter, Ramseier, Pamela, Küry, Patrick, Akbar, David, Stark, Holger, Hecker, Christina, Beckmann, Nicolau, Gliem, Michael, Nasiri, Milad, Martin, Elodie, Albrecht, Philipp, Zalc, Bernard   +26 more
core   +1 more source

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

Neurological Research and Practice, 2022
Background Therapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing–remitting MS, whereas few therapies are available for progressive forms of MS, in particular secondary progressive MS (SPMS). The approval
Liesa Regner-Nelke, Marc Pawlitzki, Alice Willison, Leoni Rolfes, Sinem-Hilal Oezalp, Christopher Nelke, Tristan Kölsche, Melanie Korsen, Matthias Grothe, Sergiu Groppa, Felix Luessi, Sinah Engel, Gereon Nelles, Eckhard Bonmann, Holger Roick, Anke Friedrich, Philipp Knorn, Harald Landefeld, Zoltan Biro, Michael Ernst, Antonios Bayas, Martina Menacher, Katja Akgün, Christoph Kleinschnitz, Tobias Ruck, Tjalf Ziemssen, Refik Pul, Sven G. Meuth   +27 more
doaj   +1 more source

Anti-inflammatory Effects of Siponimod in a Mouse Model of Excitotoxicity-Induced Retinal Injury

, 2023
Glaucoma is a leading cause of permanent blindness worldwide and is characterized by neurodegeneration linked to progressive retinal ganglion cell (RGC) death, axonal damage, and neuroinflammation.
V Palanivel (14649416), N Chitranshi (13363776), D Basavarajappa (13376013), Y You (13285080), Veer Gupta (13072143), A Klistorner (13424715), V Gupta (7723049), M Mirzaei (9999812), D Viswanathan (17016270), R Vander Wall (13424805), SL Graham (14583932)   +10 more
core  

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

, 2020
Background: Siponimod, interferon beta-1a (IFNβ-1a), IFNβ-1b and natalizumab have been evaluated as treatments for secondary progressive multiple sclerosis (SPMS) in separate randomized controlled trials (RCTs), but not head-to-head.
Nicolas Rouyrre (8631231), Anja Haltner (8631228), Imtiaz A. Samjoo (8393112), Richard Nicholas (790649), Nicholas Adlard (838615), Evelyn Worthington (8631225), Frank Dahlke (5622155), Chris Cameron (696037)   +7 more
core   +1 more source

Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate

Nature Communications, 2022
Liu et al. report structures of human sphingosine 1-phosphate (S1P) receptor 1 (S1P1) in complex with Gi and S1P or the multiple sclerosis (MS) drug Siponimod, as well as human lysophosphatidic acid (LPA) receptor 1 (LPA1) in complex with Gi and LPA ...
Shian Liu, Navid Paknejad, Lan Zhu, Yasuyuki Kihara, Manisha Ray, Jerold Chun, Wei Liu, Richard K. Hite, Xin-Yun Huang   +8 more
doaj   +1 more source

Defining Activity‐Based Subgroups in Multiple Sclerosis: A Review and Framework Proposal

European Journal of Neurology, Volume 33, Issue 6, June 2026.
ABSTRACT Background Multiple sclerosis (MS) is commonly stratified into activity‐based subgroups to inform treatment decisions and health technology assessments (HTAs). However, the terminology and criteria used to define these subgroups, particularly ‘active’, ‘highly active’ and ‘rapidly evolving severe’ (RES) disease, are inconsistent across ...
Catalina Lopez Manzano, Claire M. Rice, Emma Tallantyre, Chris Cooper, Hanyu Wang, Eve Tomlinson, Ayman Sadek, Ananya Rao‐Middleton, Howard Thom, Penny Whiting   +9 more
wiley   +1 more source

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 736-746, April 2026.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects

, 2015
Objective: To evaluate the cardiac and pulmonary effects of siponimod (BAF312) and propranolol co-administration in healthy subjects. Methods: Healthy subjects (n = 76) were randomized in a doubleblind manner to receive propranolol at siponimod steady ...
Veldandi, Uday Kiran, Polus, Florine, Legangneux, Eric, Biswal, Shibadas, Pal, Parasar   +4 more
core   +1 more source

Impact of the sphingosine-1-phosphate receptor modulator siponimod on functional phenotypes of microglia [PDF]

Over the last decades the number of drugs for the therapy of relapsing remitting multiple sclerosis (RRMS) increased significantly, whereas various approaches to develop an efficient therapy for secondary progressive multiple sclerosis (SPMS) remained ...
Steinleitner, Marlene Carmen Julie
core   +1 more source